Expression of Apolipoprotein L1 Risk Variants at the Plasma Membrane and Haplotype-Dependent Cytotoxicity
Journal of the American Society of Nephrology · 2026-11 · 37 (11) · 2450-2469
DOI: 10.1681/asn.0000001159 ↗Abstract
Key Points Apolipoprotein L1 variants were transported to the plasma membrane via actin filaments, where they exhibited distinct dynamics. Apolipoprotein L1 was functionally expressed at the plasma membrane and formed a voltage-dependent non-selective cation-permeable pore. Influx of calcium from the extracellular medium was the primary origin of the increased cytosolic calcium crucial for Apolipoprotein L1 cytotoxicity. Background The mechanisms by which apolipoprotein L1 ( APOL1 ) risk variants, G1 and G2, induce kidney disease in individuals of African ancestry remain contentious. Methods In this study, we utilized a heterologous expression system of HEK-293 cells and human podocytes to investigate APOL1-mediated cytotoxicity using genetic, electrophysiological, and microscopy-based approaches. Results APOL1 variants showed dynamic transport in vesicle-like structures toward the plasma membrane via actin filaments. At the plasma membrane, the non-risk APOL1 G0 and risk variants formed non-selective cation-permeable pores for Na + and Ca 2+ , exhibiting functional activity under basal conditions. Extracellular Ca 2+ was identified as the primary source of Ca 2+ influx through APOL1, leading to cytotoxicity. APOL1 risk variants exhibited increased basal channel activity compared to non-risk APOL1 G0, resulting in haplotype-dependent cytotoxicity. Furthermore, we observed that both the M1 (N264K) variant and APOL1 inhibitor, Inaxaplin, exerted protective effects on cell viability by blocking the APOL1-dependent intracellular Ca 2+ influx. Conclusions This study demonstrated APOL1 to be a membrane protein involved in the influx of Ca 2+ from the extracellular medium. Increased activity of APOL1 led to markedly increased cytotoxicity, which supports the gain-of-function theory. This effect was prevented by the presence of N264K variant or treatment with the APOL1 inhibitor, Inaxaplin.
EUVIMED